1 |
Wacher, V.J., Salphati, L., Benet, L.Z., 2001. Active secretion and enterocytic drug metabolism barriers to drug absorption. Adv. Drug Deliv. Rev. 46, 89-102.
DOI
|
2 |
Wallin, R., Sane, D.C., Hutson, S.M., 2002. Vitamin K 2,3-epoxide reductase and the vitamin K-dependent gamma-carboxylation system. Thromb Res. 108, 221-226.
DOI
|
3 |
Yusa, K., Tsuruo, T., 1989. Reversal mechanism of multidrug resistance by verapamil: direct binding of verapamil to P-glycoprotein on specific sites and transport of verapamil outward across the plasma membrane of K562/ADM cells. Cancer Res. 49, 5002-5006.
|
4 |
Zhu, M., Chan, K.W., Ng, L.S., Chang, Q., Chang, S., Li, R.C., 1999. Possible influences of ginseng on the pharmacokinetics and pharmacodynamics of warfarin in rats. J. Pharm. Pharmacol. 51, 175-180.
DOI
ScienceOn
|
5 |
Mungall, D.R., 1985. Population pharmacokinetics of racemic warfarin in adult patients. J. Pharmacokinet. Biopharm. 13, 213-227.
DOI
|
6 |
Nakabeppu, H., Asada, M., Oda, T., Shinozaki, Y., Yajima, T., 1996. Plasma and urinary metabolites of efonidipine hydrochloride in man. Xenobiotica 26, 229-239.
DOI
|
7 |
Nishio, S., Watanabe, H., Kosuge, K., Uchida, S., Hayashi, H., Ohashi, K., 2005. Interaction between amlodipine and simvastatin in patients with hypercholesterolemia and hypertension. Hypertens. Res. 28, 223-227.
DOI
|
8 |
Saeki, T., Ueda, K., Tanigawara, Y., Hori, R., Komano, T., 1993. Pglycoprotein- mediated transcellular transport of MDR-reversing agents. FEBS Lett. 324, 99-102.
DOI
|
9 |
Scordo, M.G., Pengo, V., Spina, E., Dahl, M.L., Gusella, M., Padrini, R., 2002. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin. Pharmacol. Ther. 72, 702-710.
DOI
|
10 |
Shimizu, M., Ogawa, K., Sasaki, H., Uehara, Y., Otsuka, Y., Okumura, H., Kusaka, M., Hasuda, T., Yamada, T., Mochizuki, S., 2003. Effects of efonidipine, an L- and T-Type dual calcium channel blocker, on heart rate and blood pressure in patients with mild to severe hypertension: an uncontrolled, open-label pilot study. Current Ther. Res. 64, 707-714.
DOI
|
11 |
Stoysich, A.M., Lucas, B.D., Mohiuddin, S.M., Hilleman, D.E., 1996. Further elucidation of pharmacokinetic interaction between diltiazem and warfarin. Int. J. Clin. Pharmacol. Ther. 34, 56-60.
|
12 |
Tamura, T., Saigusa, A., Kokubun, S., 1991. Mechanisms underlying the slow onset of action of a new dihydropyridine, NZ-105, on a cultured smooth muscle cell line. Naunyn. Schmiedebergs. Arch. Pharmacol. 343, 405-410.
|
13 |
Tanaka, T., Tsutamoto, T., Sakai, H., Fujii, M., Yamamoto, T., Horie, M., 2007. Comparison of the effects of efonidipine and amlodipine on aldosterone in patients with hypertension. Hypertens. Res. 30, 691-697.
DOI
|
14 |
Harmsze, A.M., Robijns, K., van Werkum, J.W., Breet, N.J., Hackeng, C.M., Ten Berg, J.M., Ruven, H.J., Klungel, O.H., de Boer, A., Deneer, V.H., 2010. The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response. Thromb Haemost. 103, 920-925.
DOI
ScienceOn
|
15 |
Hirsh, J., Dalen, J.E., Anderson, D.R., Poller, L., Bussey, H., Ansell, J., Deykin, D., Brandt, J.T., 1998. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 114, 445-469.
DOI
|
16 |
Holford, N.H.G., 1986. Clinical pharmacokinetics and pharmacodynamics of warfarin: understanding the dose-effect relationship. Clin. Pharmacokinet. 11, 483-504.
DOI
|
17 |
Kaminsky, L.S., Zhang, Z.Y., 1997. Human P450 metabolism of warfarin. Pharmacol. Ther. 73, 67-74.
DOI
|
18 |
Lewis, D.F.V., 1996. Cytochrome P450. Substrate specificity and metabolism. In: Cytochromes P450. Structure, Function, and Mechanism. Taylor & Francis: Bristol: 122-123.
|
19 |
Kelly, P.A., Wang, H., Napoli, K.L., Kahan, B.D., Strobel, H.W., 1999. Metabolism of cyclosporine by cytochromes P450 3A9 and 3A4. Eur. J. Drug. Metab. Pharmacokinet. 24, 321-328.
DOI
|
20 |
Kim, M.J., Nafziger, A.N., Kashuba, A.D., Kirchheiner, J., Bauer, S., Gaedigk, A., Bertino, J.S. Jr., 2006. Effects of fluvastatin and cigarette smoking on CYP2C9 activity measured using the probe S-warfarin. Eur. J. Clin. Pharmacol. 62, 431-436.
DOI
|
21 |
Lilja, J.J., Backman, J.T., Neuvonen, P.J., 2005. Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of racemic warfarin in healthy subjects. Br. J. Clin. Pharmacol. 59, 433-439.
DOI
|
22 |
Masuda, Y., Takeguchi, M., Arakawa, C., Sakai, T., Hibi M., Tanaka, S., Shigenobu, K., Kasuya, Y., 1990. Antihypertensive and diuretic effects of NZ-105, a novel dihydropyridine derivative. Arch. Int. Pharmacodyn. Ther. 304, 247-264.
|
23 |
Abernethy, D.R., Kaminsky, L.S., 1991. Dickinson TH. Selective inhibition of warfarin metabolism by diltiazem in humans. J. Pharmacol. Exp. Ther. 257, 411-415.
|
24 |
Benet, L.Z., Cummins, C.L., Wu, C.Y., 2003. Transporter-enzyme interactions: implications for predicting drug-drug interactions from in vitro data. Curr. Drug Metab. 4, 393-398.
DOI
|
25 |
Bogaards, J.J., Bertrand, M., Jackson, P., Oudshoorn, M.J., Weaver, R.J., van Bladeren, P.J., Walther, B., 2000. Determining the best animal model for human cytochrome P450 activities: a comparison of mouse, rat, rabbit, dog, micropig, monkey and man. Xenobiotica 30, 1131-1152.
DOI
|
26 |
Cummins, C.L., Jacobsen, W., Benet, L.Z., 2002. Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J. Pharmacol. Exp. Ther. 300, 1036-1045.
DOI
|
27 |
Cao, X., Gibbs, S.T., Fang, L., Miller, H.A., Landowski, C.P., Shin, H.C., Lennernas, H., Zhong, Y., Amidon, G.L., Yu, L.X., Sun, D., 2006. Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. Pharm. Res. 23, 1675-1686.
DOI
|
28 |
Choi, D.H., Chang, K.S., Hong, S.P., Choi, J.S., 2008. Effect of atrovastatin on intravenous and oral pharmacokinetics of verapamil in rats. Biopharm. Drug Dispos. 29, 45-50.
DOI
|
29 |
Choi, J.S., Piao, Y.J., Han, H.K., 2006. Phatmacokinetics interaction between fluvastatin and diltiazem in rats. Biopharm. Drug Dispos. 27, 437-441.
DOI
|
30 |
Darvari, R., Boroujerdi, M., 2004. Concentration dependency of modulatory effect of amlodipine on P-glycoprotein efflux activity of doxorubicin - a comparison with tamoxifen. J. Pharm. Pharmacol. 56, 985-991.
DOI
ScienceOn
|
31 |
Guengerich, F.P., Martin, M.V., Beaune, P.H., Kremers, P., Wolff, T., Waxman, D.J., 1986. Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J. Biol. Chem. 261, 5051-5060.
|